Boehringer Ingelheim, the maker of Viramune (nevirapine), announced that it has begun enrolling participants in a clinical trial of an extended-release formulation of the drug for once-daily dosing. The current formulation of Viramune is approved for use in the U.S. at a dose of 200 mg twice a day. The dose being studied is 400 mg once a day.
The new formulation will be tested in the VERXVE study, which will pair it with Truvada (tenofovir and emtricitabine), and compare it to the current twice-a-day formulation of Viramune, also paired with Truvada. The study will enroll 1,000 patients in 18 countries, who’ve never taken antiretroviral therapy before.
The study will enroll patients throughout 2008, and results are expected in 2010.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Previous Comments:
comments 1 - 6 (of 6 total)
tim, , 2008-02-19 09:22:39
Interesting that I've been on this once a day combo since Nov 2006. And the drug company is just getting around to studying this. Am I missing something?
Adam, , 2008-02-18 21:24:51
I have taken viramune once daily since April 2005. Viral still undectable
ken, , 2008-02-17 20:04:20
I take this cocktail,no side effects,counts are the best since the early 90's,so I'm very excited to see the outcome
Lane Kelly-King, Atlanta, 2008-02-17 18:15:10
I have been taking once daily virumune for about 2 mos.I just have my labs done last fri. I do combivir as part of my cocktail. I was on it before then took a 3 yr holiday and started back on it about a yr ago. They are all still working. I have had no problems with the dosage change whatsoever.
Rick, HOUSTON, 2008-02-13 13:23:43
Correction to my posting. I have been taking "once a-day" Travada/Viramune since June '07, not December as stated.
Rick, HOUSTON, 2008-02-13 13:06:34
Interesting article. I have been doing "once a-day" since starting on Travada/Viramune in Dec '07. No problems!!
